An interventional study of Active Sports Shoes and Usual Shoes in Chronic Obstructive Pulmonary Disease (COPD), Dyspnoea and Exercise Intolerance, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 8 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Assistance Publique - Hôpitaux de Paris.
Among the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 12 with no phase, and was the 20th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–84
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 35+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 17 interventional studies, 102 across the 4 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
| NCT07445750Assistance Publique - Hôpitaux de ParisSports Shoes and the Six-Minute Walk Test in COPD | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
COPD: A Leading Cause of Respiratory Disability COPD, primarily linked to smoking, affects 3.5 million people in France and causes 15,000 deaths each year. It is a major source of disability, particularly due to dyspnoea, which affects one in three patients. Around 400,000 patients are registered under long-term conditions (ALD), and 200,000 receive home-based respiratory support. The most severe cases fall under the category of chronic respiratory failure-a term also applicable to other respiratory or neuromuscular diseases.
Walking Exposes Physical Limitations In patients with respiratory failure, walking rapidly induces disabling dyspnoea, as it may represent their maximal effort. This severely limits autonomy and quality of life. To improve exercise tolerance, clinicians rely on pulmonary rehabilitation (exercise reconditioning, bronchodilators, oxygen therapy). When these measures are insufficient, mobility aids such as scooters or electric scooters may help, although they have limitations (cost, bulkiness, muscular deconditioning).
The Six-Minute Walk Test (6MWT): A Key Tool The 6MWT is a standardised test that assesses walking distance, dyspnoea, heart rate, and oxygenation. It is used to evaluate the severity and prognosis of respiratory failure and to measure response to treatment. It is integrated into prognostic indices and criteria for assessing the effectiveness of rehabilitation. The only non-standardised parameter remains the type of footwear worn.
Research Hypothesis Some so-called "active" sports shoes enhance walking by design-through cushioning, rocker soles, and rigid inserts-which store and return impact energy to assist propulsion. We hypothesise that wearing such shoes could improve walking performance in COPD patients, as reflected by a greater distance on the 6MWT. If confirmed, this simple and low-cost solution could meaningfully improve the daily lives of many patients.
Chronic obstructive pulmonary disease (COPD) is a leading cause of respiratory disability and impaired quality of life, particularly due to exertional dyspnoea. In patients with moderate to severe disease, walking can trigger disabling breathlessness, effectively limiting autonomy and social participation. While pulmonary rehabilitation, pharmacological treatments, and oxygen therapy can improve exercise tolerance, some patients continue to experience debilitating limitations. Mobility aids such as scooters are sometimes proposed but carry risks of deconditioning and are not always practical or accessible.
The six-minute walk test (6MWT) is a standardised and widely used measure of submaximal functional capacity in COPD. It provides prognostic and therapeutic insights, but one parameter remains non-standardised: the type of footwear used by patients during the test. This study explores the hypothesis that biomechanically optimised "active" sports shoes-designed to enhance gait efficiency through energy-returning cushioning, curved ("rocker") soles, and stiff inserts-may significantly improve walking performance in individuals with COPD.
ChaussePnée is a randomised, open-label, controlled, cross-over trial comparing two walking conditions in the same patient: wearing "active" sports shoes versus their usual, "normal" shoes. The primary objective is to detect a difference in walking distance during the 6MWT between the two conditions. Secondary objectives include assessments of symptom tolerance (dyspnoea, leg fatigue), physiological responses (heart rate, oxygen saturation), perceived comfort, and biomechanical efficiency during walking and stair climbing.
Patients will be recruited during hospitalisation in a respiratory rehabilitation unit. Eligible participants will be adults with a confirmed diagnosis of COPD, with severe to very severe airflow obstruction (FEV1 \< 50% predicted), and dyspnoea classified as grade 3 or 4 on the modified Medical Research Council (mMRC) scale. All participants will have a clinical indication for 6MWT as part of their care.
Each participant will undergo two 6MWTs and two stair climbing tests on the same day, at a dedicated clinical investigation centre. The sequence of shoe conditions will be randomised. Between tests, sufficient rest periods will be ensured. Standardised instructions and outcome measures (including distance, Borg scales, comfort ratings, vital signs, and optional metabolic measurements) will be used.
An ancillary study, offered to a subset of participants, will include continuous spirometric and metabolic assessments during the tests, aiming to clarify underlying physiological mechanisms (e.g., energy expenditure, hyperventilation, dynamic hyperinflation). Motion capture and force platform analysis will quantify gait biomechanics. In-shoe pressure mapping will compare load distribution across footwear conditions.
The study plans to enrol 75 patients. Sample size was calculated based on a minimal clinically important difference of 22.8 metres in 6MWT distance, assuming an SD of 53.6m and a power of 80-90%. The main analysis will compare intra-individual differences in 6MWT distance using paired statistical tests and linear mixed models accounting for period and sequence effects. Secondary outcomes will be analysed similarly.
The study duration is 12 months, with a single study visit for each participant. Risks are minimal, as all procedures are non-invasive and part of standard respiratory evaluation. Participants will travel to the evaluation centre by covered medical transport, and no medication or biological sampling is involved. The anticipated benefit is both individual (raising awareness of the role of footwear in daily life) and collective (identifying a simple, low-cost intervention to support mobility in COPD).
Inclusion Criteria:
Non inlcusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Wearing biomechanically optimised "active" sports shoes
Other: Active Sports Shoes
Wearing the patient's usual "normal" shoes
Other: Usual Shoes
Biomechanically optimised footwear featuring high energy-return cushioning, rocker sole geometry, and rigid inserts, worn during walking and stair-climbing tests to assess impact on physical performance in COPD patients.
The patient's own everyday footwear, worn during walking and stair-climbing tests, serving as a control condition to compare with biomechanically optimised sports shoes.
Distance walked during the six-minute walk test (6MWT)
Comparison of walking distance (in metres) between two conditions-wearing active sports shoes versus usual shoes-measured in the same patient using standardised six-minute walk tests.
Time frame: Within one day (two tests performed on the same day)
Completion and performance of a stair-climbing test
Assessment of the ability to complete one flight of stairs and related performance metrics (time taken, number of steps, need to pause), comparing the active shoes versus usual shoes condition in the same patient.
Time frame: Within one day (two tests performed on the same day)
Change in dyspnoea intensity (Borg scale)
Dyspnoea intensity will be assessed using the modified Borg Category-Ratio 10 (CR10) scale (range 0-10), where 0 will indicate "no breathlessness at all" and 10 will indicate "maximal breathlessness." Higher scores will reflect greater dyspnoea severity. Change in dyspnoea intensity will be calculated as the difference between post-intervention and baseline scores (post minus baseline), with negative values indicating an improvement (reduction) in dyspnoea.
Time frame: Within one day (start and end of each 6MWT and stair test)
Change in lower limb fatigue (Borg scale)
Fatigue intensity will be assessed using the modified Borg Category-Ratio 10 (CR10) scale (range 0-10), where 0 will indicate "no fatigue at all" and 10 will indicate "maximal fatigue." Higher scores will reflect greater fatigue severity. Change in fatigue intensity will be calculated as the difference between post-intervention and baseline scores (post minus baseline), with negative values indicating an improvement (reduction) in fatigue.
Time frame: Within one day (end of each 6MWT and stair test)
Change in foot pain (Borg scale)
Pain in the feet will be assessed using the modified Borg Category-Ratio 10 (CR10) scale (range 0-10), where 0 will indicate "no pain at all" and 10 will indicate "maximal pain." Higher scores will reflect greater pain severity. Change in foot pain intensity will be calculated as the difference between post-intervention and baseline scores (post minus baseline), with negative values indicating an improvement (reduction) in pain.
Time frame: Within one day (end of each 6MWT and stair test)
Comfort rating of the shoes
Perceived comfort of the shoes, scored on a 0-10 numeric rating scale (0 = extremely uncomfortable, 10 = extremely comfortable), comparing active versus usual shoes.
Time frame: Within one day (end of each 6MWT and stair test)
Comfort rating of the shoes
Short version of patient questionnaire of "confort rating of the shoes", comparing active versus usual shoes.
Time frame: Within one day (end of each 6MWT )
Change in heart rate
Variation in heart rate from start to end of each test, measured via pulse oximetry, comparing active versus usual shoes.
Time frame: Within one day (start and end of each 6MWT and stair test)
Change in oxygen saturation (SpO₂)
Variation in oxygen saturation measured non-invasively before and after each test, comparing active versus usual shoes.
Time frame: Within one day (start and end of each 6MWT and stair test)
Change in breathing frequency
Variation in breathing frequency from start to end of each test, comparing active versus usual shoes.
Time frame: Within one day (start and end of each 6MWT and stair test)
Biomechanical gait parameters
Kinematic analysis of gait using motion capture
Time frame: Within one day (during the walking tests)
Thoracic respiratory parameters
Kinematics of breathing using motion capture
Time frame: Within one day (during the walking tests)
Foot pressure distribution
Plantar pressure mapping collected with in-shoe sensors during brief standing and walking periods, comparing pressure distribution between active and usual shoes.
Time frame: Within one day (static and walking trials)
Oxygen consumption during effort
Measurement of oxygen consumption using a portable metabolic system (Cosmed K5) to compare energy expenditure between footwear conditions in a subset of patients.
Time frame: Within one day (during 6MWT and stair test, ancillary study only)
Inspiratory capacity during effort
Spirometric measurement of inspiratory capacity during effort to assess dynamic hyperinflation, comparing footwear conditions in a subset of patients.
Time frame: Within one day (during 6MWT and stair test, ancillary study only)
Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Assistance Publique - Hôpitaux de Paris →